Leadership & Management
Stallergenes Greer appoints new country leader for ANZ in an internal promotion

Leadership & Management: Stallergenes Greer, a biopharmaceutical leader specialising in respiratory, food, and venom allergies, has appointed Rachel Sutherland as Country Manager for Australia & New Zealand. Sutherland has been with the company for four years, most recently serving as the Director of Commercial Operations for ANZ, prior to her promotion.
“I am excited to transition to the role of Country Manager, Australia & New Zealand,” said Sutherland. “Leading a team of ANZ professionals, we are focused on strengthening relationships with HCPs, patient organisations and the peak professional body to expand the awareness of allergen and venom immunotherapy treatments, offering greater access to a range of evidence-based treatments and long-term hope for patients suffering from respiratory and venom allergies.”
With over two decades of experience in pharmaceuticals and healthcare across commercial, sales, marketing, and patient engagement roles, Sutherland’s leadership and business acumen are set to drive growth in the ANZ market.
The company supplies a portfolio of evidence-based allergen and venom immunotherapy treatments, along with diagnostic devices, tailored for the ANZ market.
Recently, the Stallergenes Greer Foundation Science Award for Allergy was bestowed upon Associate Professor Rachel Peters of the Murdoch Children’s Research Institute. Her research addresses the significant link between food allergies and respiratory health, impacting up to 10% of children.
A/Prof Jennifer Koplin from The University of Queensland’s Child Health Research Centre was also honoured by the Foundation for her work on peanut allergies in infants.
These recognitions highlight Stallergenes Greer’s commitment to advancing allergy research and precision medicine.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More